Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotinamide mononucleotide + DC cell vaccine
- Development stage
- Unknown
- Lead developer
- Shanghai Cell Therapy Group
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Oral (nmn), Injection (dc Cell Vaccine)
01
Overview
This is a **combination therapy** consisting of **nicotinamide mononucleotide (NMN)** and a **dendritic cell (DC) vaccine**. NMN is a precursor of NAD^+, a key coenzyme involved in cellular metabolism, DNA repair, and regulation of immune responses. It is investigated for its potential to ameliorate aging-related disorders and to support cellular health, including effects on DNA repair, mitochondrial function, autophagy, and immune cell activity[9]. The DC cell vaccine is an immunotherapy modality where dendritic cells, the body's primary antigen-presenting cells, are activated and injected to stimulate a robust anti-tumor immune response by priming T cells and inducing cytotoxic lymphocyte and memory T cell formation[8][6][4][2]. The combination is being studied for its ability to enhance the immunotherapeutic and antitumor effects of DC-based vaccination post-surgery in oncology settings, aiming to improve patient outcomes, immune system diversity, and biomarkers of biological age[5].
- Brand names
- Vital NAD
- Other names
- nicotinamide mononucleotide + dendritic cell vaccine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on nicotinamide mononucleotide + DC cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotinamide mononucleotide + DC cell vaccine.